iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update

SAN DIEGO, Aug. 28, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, today announced its financial results for the fiscal year ended June 30, 2026, and provided a corporate update on its progress.

“Fiscal year 2026 was a transformative year for iBio, most importantly marked by our transition to a clinical-stage company with the initiation of the Phase 1 clinical trial of IBIO-600, a potentially best-in-class, long-acting anti-myostatin monoclonal antibody designed to preserve muscle and improve body composition,” said Martin Brenner, Ph.D., DVM, Chief Executive Officer and Chief Scientific Officer of iBio. “Additional highlights came from our IBIO-610 program, where we presented preclinical data supporting its potential for fat-selective weight loss, complementing with current GLP-1 therapies by increasing fat loss while preserving lean mass, and to reduce weight regain following GLP-1 discontinuation. We are excited to build on this progress as we continue advancing our pipeline and working toward our mission of delivering transformative treatments to patients.”